Beinaglutide

Modify Date: 2025-08-25 10:38:07

Beinaglutide Structure
Beinaglutide structure
Common Name Beinaglutide
CAS Number 123475-27-4 Molecular Weight 3298.61
Density N/A Boiling Point N/A
Molecular Formula C149H225N39O46 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of Beinaglutide


Beinaglutide is a recombinant human GLP-1 (rhGLP-1) that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH)[1][2].

 Names

Name Beinaglutide

 Beinaglutide Biological Activity

Description Beinaglutide is a recombinant human GLP-1 (rhGLP-1) that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH)[1][2].
Related Catalog
In Vitro Beinaglutide (100 nM; 48 h) increases the expression of phosphorylation of Akt in the adipocytes that were potentiated insulin-stimulated[2]. Western Blot Analysis[2] Cell Line: 3T3L-1 cells Concentration: 100 nM Incubation Time: 48 h Result: Increased the phosphorylation of Akt in the adipocytes that were potentiated insulin-stimulated.
In Vivo Beinaglutide (0.6, 1.2, 2.4 mg/kg; s.c.; three times per day for 7 consecutive days) shows the ability of glycemic contro, inhibits food intake and weight loss in mouse[1]. Beinaglutide (150 µg/kg; s.c.; daily for 6 weeks) increases insulin sensitivity of adipocytes[2]. Animal Model: Wild-type male C57BL/6 mice and Male Lepob/Lepob (ob/ob) mice (ob/ob-NASH mouse model was induced by GAN diet)[1] Dosage: 0.6, 1.2, 2.4 mg/kg Administration: S.c.; three times per day for 7 consecutive days Result: Significantly reduced blood glucose with dosedependence in C57BL/6 and ob/ob mice, dose dependently inhibits food intake and gastric Emptying, and significantly reduced body weight, food intake with dose-dependence. Animal Model: Eight-week-old male C57BL/6 mice[2] Dosage: 150 µg/kg Administration: S.c.; daily for 6 weeks Result: Showed improved glucose tolerance and insulin sensitivity, decreased adipose tissue weight and adipocyte size and potentiated insulin sensitivity of adipocytes.
References

[1]. Fang X, et al. Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model. Life Sci. 2021 Apr 1;270:118966.

[2]. Zhang F, et al. Recombinant human GLP-1 beinaglutide regulates lipid metabolism of adipose tissues in diet-induced obese mice. iScience. 2021 Oct 30;24(12):103382.

 Chemical & Physical Properties

Molecular Formula C149H225N39O46
Molecular Weight 3298.61
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.